Home Liquid Biopsy Market Size And Forecast : Report 2024-2032

Liquid Biopsy Market Size And Forecast : Report 2024-2032

Business

October 14, 2024

As per Renub Research’s latest report titled “Liquid Biopsy Market Report by Product (Kits & Reagents, Platforms & Instruments, and Services), Application (Cancer Therapeutic Application, Reproductive Health, and Other Therapeutic), Circulating Biomarkers (Circulating Tumour Cell, Circulating Tumour DNA, and Cell-free DNA), End-User (Hospitals, Diagnostic Laboratories, Point-of-care Testing, Academic Institutes, and Others) Countries and Company Analysis 2024-2030″ Global Liquid Biopsy Market Size is projected to reach around US$ 10.08 Billion by 2030 from worth US$ 3.73 Billion in 2023, with a CAGR of 15.26% between 2024 and 2030. The noninvasive or minimally detection of spreading tumor-derived components in biofluids like blood, and liquid biopsy, is a revolutionary technique with significant potential for cancer management. Liquid biopsies enable medical professionals to discover several factors concerning a tumor via a patient’s Plasma / Serum, Urineblood sample. The liquid biopsy enables medical professionals to comprehend which treatments are most suitable for the cancer patient.

Notwithstanding, liquid biopsies are a beneficial option to surgical biopsies in the case of patients whose tissue is unfit to be biopsied or as an addition to comprehensively evaluating medicine response. These methods also allow medical professionals to obtain serial samples during the treatment process (which is not carried out in the case of a tumor biopsy) to evaluate the advancement of the tumor and drug resistance in the patient.

Furthermore, the liquid biopsy industry is experiencing growth due to advancements such as next-generation sequencing for developed cancer patients in liquid biopsies, an expanded number of cancer patients, and improved patient preference for minimally invasive treatments. On the contrary, with an increase in healthcare expenditure in developing countries, such as China and India, liquid biopsy tests to dine rare cancers are anticipated to present ample opportunities for liquid biopsies market growth.

OVID-19 Impact on Global Liquid Biopsy Market:

The remarkable impact of COVID-19 has been far-reaching, but the effects on cancer patients make them one of the poorest affected groups. COVID-19 has profoundly affected the number of patients undergoing cancer diagnosis, screening, and treatment. The increased pressure due to the growing rate of COVID-19 patients’ hospitalization led to the re-profiling of many hospitals and departments, including oncology clinics for treating patients with COVID-19. Further, the pandemic has also affected the logistics and supplies of cancer raw materials, diagnostic components, and other essential commodities utilized in the production of liquid biopsies. These aspects restrict the development of the liquid biopsy industry during COVID-19.

The Europe region would exhibit the highest growth:

Regionally, Europe Liquid biopsy is one of the fastest markets. The liquid biopsy technique provides a comparative noninvasive, susceptible, and information-rich profile of the disease in a time frame that is half of the conventional tissue biopsy. The Europe Liquid biopsy market comprises Germany, France, the U.K., Italy, Spain, and the rest of Europe. Germany is the largest industry for liquid biopsy in Europe, followed by UK and France.

In Europe clinical applications, the liquid biopsy market has been segmented into Monitoring, Theranostics, and Prognosis & Screening. The therapy selection is the method applied to evaluate the relief or even the cure of the diseases. Monitoring the recurrence of cancer is one of the essential parts involving routine physical exams and medical imaging in Europe. The early cancer screening procedure starts with the suspicious lesions found by CT scan, and the liquid biopsy ensures their property identification.

Lung cancer accounts for the largest market:

Based on Cancer, the liquid biopsy market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others. Worldwide by cancer type lung cancer is the most common cancer. For instance, as per the (WHO) World Health Organization, lung cancer is the highest cause of cancer death among females and males, estimated to have around 1.80 Million deaths worldwide in 2020. Thus, a simple liquid biopsy is playing an increasingly important role in lung cancer treatment. Lung cancer is to dominate the liquid biopsy market due to the rising prevalence of non-small cell lung cancer globally.

By circulating biomarkers, the liquid biopsy market is divided into circulating tumor DNA, circulating tumor cells, extracellular vesicle, and other biomarkers. The circulating tumor cell segment generated the highest revenue, owing to the increased number of clinically imperative tests with genomic analyses. Further, circulating tumor DNA is the fastest-growing segment due to the rapid development of next-generation sequencing (NGS) technologies in liquid biopsy advancements applied to circulating tumor DNA (ctDNA).

Key Players:

Prominent companies operating in the global liquid biopsy industry include Thermo Fisher Scientific, Inc, Guardant Health, Inc, EXACT Sciences Corp, Illumina Inc., Bio–Rad Laboratories, Biocept, NeoGenomics, Inc., Qiagen NV.

Anxiety Disorder and Depression Treatment Market will increase from US$ 19.39 billion in 2023 to US$ 32.25 billion by 2032 at a CAGR of 5.82% from 2024-2032.

The Global Rapid Acting Insulin Market will reach US$ 11.17 billion by 2032, up from US$ 7.36 billion in 2023, with a CAGR of 4.75 % between 2024 and 2032.

Market Summary:

Region – This Report covers by Region in the 5 viewpoints (Europe, North America, Asia-Pacific Latin America, and Middle East/Africa)
Cancer – Liquid Biopsy Market has been covered from 5 viewpoints (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer & Others)
Product – Renub Research Report covers by product in the 4 viewpoints (Kits & Consumables, Instruments and Services)
Sample – Our Report covers by sample in the 3 viewpoints (Plasma/Serum, Urine & Others)
Circulating Biomarkers – Liquid Biopsy Market has been covered from 4 viewpoints (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) & Exosomes), Clinical Application (Monitoring, Theranostics, Prognosis & Screening)
Clinical Application – Liquid Biopsy Market has been covered from 4 viewpoints (Monitoring, Theranostics, Prognosis & Screening)
All the major players have been covered from 3 Viewpoints (Overview, Recent Development, and Revenue Analysis) Thermo Fisher Scientific, Inc, Guardant Health, Inc, EXACT Sciences Corp, Illumina Inc., Bio – Rad Laboratories, Biocept, NeoGenomics, Inc., Qiagen NV.

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.